Straits Times Index
3,137.54 +25.89 (+0.83%) S&P 500
3,911.74 +116.01 (+3.06%) Dow
31,500.68 +823.28 (+2.68%) Nasdaq
11,607.62 +375.42 (+3.34%) BTC-USD
21,427.51 +12.42 (+0.06%) CMC Crypto 200
467.40 +13.50 (+2.98%)
Kyowa Kirin Co., Ltd. (KYKOF)
| Previous close | 21.58 |
| Open | 21.53 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 21.58 - 21.58 |
| 52-week range | 21.22 - 36.25 |
| Volume | |
| Avg. volume | 680 |
| Market cap | 11.596B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | 28.25 |
| EPS (TTM) | 0.76 |
| Earnings date | N/A |
| Forward dividend & yield | 0.42 (1.93%) |
| Ex-dividend date | 29 Jun 2022 |
| 1y target est | N/A |
- Business Wire
MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress
SAN DIEGO & TOKYO, June 10, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that data from the zandelisib clinical development program, including the Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered
- Business Wire
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
SAN DIEGO & TOKYO, June 04, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced data from the ongoing Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta
- Business Wire
MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022
SAN DIEGO & TOKYO, May 26, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that an abstract highlighting data and information from the Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an investigational phosphatidylinosit
